Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Apellis Pharmaceuticals (APLS) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to 0.12%.

  • Apellis Pharmaceuticals' Return on Capital Employed rose 4400.0% to 0.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.12%, marking a year-over-year increase of 4400.0%. This contributed to the annual value of 0.25% for FY2024, which is 7300.0% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Return on Capital Employed is 0.12%, which was up 4400.0% from 0.31% recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' Return on Capital Employed registered a high of 0.12% during Q3 2025, and its lowest value of 0.94% during Q4 2021.
  • In the last 5 years, Apellis Pharmaceuticals' Return on Capital Employed had a median value of 0.61% in 2022 and averaged 0.56%.
  • In the last 5 years, Apellis Pharmaceuticals' Return on Capital Employed tumbled by -6500bps in 2021 and then skyrocketed by 7000bps in 2024.
  • Apellis Pharmaceuticals' Return on Capital Employed (Quarter) stood at 0.94% in 2021, then increased by 2bps to 0.92% in 2022, then decreased by -2bps to 0.93% in 2023, then surged by 75bps to 0.23% in 2024, then skyrocketed by 152bps to 0.12% in 2025.
  • Its Return on Capital Employed was 0.12% in Q3 2025, compared to 0.31% in Q2 2025 and 0.28% in Q1 2025.